Analytical Data
-
Gene name
ABCF2
- Application
-
Alternative Names
ABC-F2; ABC28; HUSSY-18; M-ABC1; Iron-inhibited ABC transporter 2
-
Species
Human
-
Source
E. coli
-
Tag
N-His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q9UG63
-
Expression Region
Ile396~Val623
-
Molecular Weight
30kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
ABCF2, a member of the ATP-binding cassette (ABC) transporter family, has garnered significant attention in recent research due to its critical role in cellular processes, including drug resistance and antigen presentation. Initially identified as an ATP-dependent protein capable of transporting various substrates, ABCF2's precise functions remain elusive, prompting extensive studies into its biological significance. The protein is particularly interesting in the context of immune responses, as it is implicated in the transport of peptides for Major Histocompatibility Complex (MHC) class I presentation, influencing the activation of CD8+ T cells. Moreover, aberrations in ABCF2 expression have been linked to several malignancies, suggesting that it may play a role in tumor biology and chemoresistance. The development of recombinant ABCF2 proteins has enabled researchers to explore its functional properties and interaction mechanisms more comprehensively, paving the way for potential therapeutic applications. By investigating the molecular dynamics and regulatory pathways associated with ABCF2, scientists aim to elucidate its role in both normal physiology and disease states, which could lead to novel strategies for overcoming drug resistance in cancer and enhancing immune responses. As such, ABCF2 not only serves as a model for understanding ABC transporter mechanisms but also represents a promising target for future therapeutic interventions.
